Building on research by a former University of Minnesota professor, Torigen Pharmaceuticals has begun in-veterinary testing of its immunooncology vaccine for companion animals.
Torigen Pharmaceuticals, a US-based veterinary cancer immunotherapy developer based on University of Minnesota research, has closed a $3.1m series A round featuring University of Connecticut-backed UConn Innovation Fund. UConn Innovation Fund, which also counts state-owned investment firm Connecticut Innovations (CI) and financial services Webster Bank as partners, is a $1.5m vehicle open to participants in…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
